Merck HIV drug fails Phase III

Merck says that its HIV drug vicriviroc failed two late-stage trials, scuttling any immediate plans to file for an approval at the FDA. Merck acquired the drug through its acquisition of Schering-Plough, which had expected an approval by the end of this year and peak sales of $500 million to $750 million. Analysts, though, had expected a much smaller peak, saying that the experience of Selzentry--another CCR5 co-receptor antagonist--indicated a limited demand for the drug. Merck plans to continue studying the drug in a treatment naïve population. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.